Search results
Jul 20, 2022 · William Stilley, Chief Executive Officer of Adial, commenting on the trial results, said, “Alcohol Use Disorder is an unmet medical need that affects tens of millions of people each year, and, based on the strength of these ONWARD results in heavy drinking patients that have the target genetics, and the fact that AD04 demonstrated an ...
- Adial Pharmaceuticals Announces Peer-Reviewed Publication ...
The publication also reported the results of a new study...
- Adial Pharmaceuticals Provides Update on Regulatory Strategy ...
Adial’s lead compound, AD04, is a genetically targeted...
- Adial Pharmaceuticals Announces Peer-Reviewed Publication ...
Apr 10, 2024 · The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with placebo in subjects with AUD in the Company’s prior Phase 3 clinical trial. The published study provides a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5 ...
Apr 10, 2024 · Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trialGLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ...
People also ask
Does Adial's AD04 for alcohol use disorder reduce heavy drinking days?
Is AD04 a safe drug for alcohol use disorder?
How does AD04 work?
Can AD04 help treat opioid use disorder?
The company says the new patent strengthens Adial’s patent portfolio and covers AD04’s ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
Apr 10, 2024 · About Adial Pharmaceuticals, Inc. ... The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment ...
Mar 6, 2023 · Adial’s lead compound, AD04, is a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and was recently investigated in a Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which were identified using the Company’s companion diagnostic genetic test.
Jul 20, 2022 · Adial Pharmaceuticals Inc's (NASDAQ: ADIL) ONWARD Phase 3 study of AD04 for Alcohol Use Disorder (AUD) achieved a statistically significant mean reduction in heavy drinking days compared to placebo.
